spacer
home > white papers > Cleaning Validation: What do you need to consider to ensure a successful outcome? - RSSL
WHITE PAPERS
logo_RSSL.jpg

RSSL

phone +44 (0)118 918 4024
web http://www.rssl.com
email University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA

Cleaning Validation: What do you need to consider to ensure a successful outcome?

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination.

The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support.

The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues.

So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>


Industry Events

Drug Delivery Partnerships 2018

22-24 January 2018, PGA National Resort & Spa, Palm Beach Gardens, Florida

For 22 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement